We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
-17.66%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$942M
AUM Growth
-$145M
Cap. Flow
+$138M
Cap. Flow %
14.65%
Top 10 Hldgs %
58.05%
Holding
40
New
8
Increased
12
Reduced
8
Closed
2

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$39.3M
2
RVMD icon
Revolution Medicines
RVMD
+$36.5M
3
TWST icon
Twist Bioscience
TWST
+$18.8M
4
CRSP icon
CRISPR Therapeutics
CRSP
+$13.8M
5
ADVM
Adverum Biotechnologies
ADVM
+$13.1M

Top Sells

Rank Stock Value
1
BOLD
Audentes Therapeutics, Inc
BOLD
+$51.5M
2
ILMN icon
Illumina
ILMN
+$8.62M
3
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$8.09M
4
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$6.39M
5
NVTA
Invitae Corporation
NVTA
+$2.92M

Sector Composition

Rank Sector Weight
1 Healthcare 92.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADVM
26
DELISTED
Adverum Biotechnologies
ADVM
$11M 1.17%
+112,500
New +$13.1M
VYGR icon
27
Voyager Therapeutics
VYGR
$181M
$10M 1.06%
1,095,075
– –
ZLAB icon
28
Zai Lab
ZLAB
$2.05B
$9.78M 1.04%
+190,000
New +$9.9M
ALLO icon
29
Allogene Therapeutics
ALLO
$635M
$9.72M 1.03%
+500,000
New +$11.9M
BMY.RT
30
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$9.5M 1.01%
2,500,000
+1,000,000
+67% +$3.29M
SGMO
31
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$9.27M 0.98%
1,455,000
– –
ILMN icon
32
Illumina
ILMN
$30B
$8.19M 0.87%
30,840
-30,840
-50% -$8.62M
ORTX
33
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$7.34M 0.78%
97,500
+15,500
+19% +$1.79M
BDTX icon
34
Black Diamond Therapeutics
BDTX
$99.7M
$7.22M 0.77%
+289,395
New +$8.81M
DCPH
35
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$5.76M 0.61%
140,000
-115,000
-45% -$6.39M
DMTK
36
DELISTED
DermTech, Inc. Common Stock
DMTK
$5.64M 0.6%
+571,713
New +$7.02M
TPTX
37
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$3.35M 0.36%
75,000
– –
STOK icon
38
Stoke Therapeutics
STOK
$1.84B
$2.75M 0.29%
120,000
-10,000
-8% -$247K
GILD icon
39
CALL
Gilead Sciences
GILD
$163B
– –
-200,000
Closed -$13M
BOLD
40
DELISTED
Audentes Therapeutics, Inc
BOLD
– –
-860,000
Closed -$51.5M
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q1 2020 Portfolio in Review

As of Q1 2020, Casdin Capital held 40 positions worth $942M, down 13% from $1.09B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Casdin Capital deployed $138M of net new capital in Q1 2020, opening 8 new positions and adding to 12 existing holdings. Its largest new stake was Revolution Medicines: 1,319,536 shares worth $28.9M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 92% a quarter earlier.

On the sell side, the largest reduction was Illumina, an estimated $8.62M trimmed.

  • Casdin Capital's largest Q1 2020 buy was Revolution Medicines: 1,319,536 shares worth $28.9M.
  • Casdin Capital added most to Blueprint Medicines in Q1 2020, an estimated $39.3M increase.
  • Casdin Capital's biggest Q1 2020 reduction was Illumina, cutting an estimated $8.62M.
  • Casdin Capital fully exited Audentes Therapeutics, Inc in Q1 2020, selling an estimated $51.5M.
  • Casdin Capital's ten largest holdings make up 58% of its $942M portfolio in Q1 2020.
  • Casdin Capital opened 8 new positions and closed 2 in Q1 2020.
  • Casdin Capital's portfolio value fell 13% quarter-over-quarter to $942M.

Based on Casdin Capital's 13F filing for Q1 2020, filed 15 May 2020.